[PDF][PDF] Targeting BRCA1 and BRCA2 deficiencies with G-quadruplex-interacting compounds

J Zimmer, EMC Tacconi, C Folio, S Badie, M Porru… - Molecular cell, 2016 - cell.com
J Zimmer, EMC Tacconi, C Folio, S Badie, M Porru, K Klare, M Tumiati, E Markkanen
Molecular cell, 2016cell.com
Summary G-quadruplex (G4)-forming genomic sequences, including telomeres, represent
natural replication fork barriers. Stalled replication forks can be stabilized and restarted by
homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs)
arising at collapsed forks. We have previously shown that HR facilitates telomere replication.
Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric
repeats is decreased significantly in cells lacking HR. Treatment with the G4-stabilizing …
Summary
G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers. Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks. We have previously shown that HR facilitates telomere replication. Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR. Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability. Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency. PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7. Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.
cell.com